How many insider trades does FilingIQ track for AKTX?

FilingIQ tracks 93 Form 4 insider transactions for AKTX (Akari Therapeutics Plc), covering filings from Nov 25, 2015 onwards. 9 of those were filed in the last 90 days.

Are AKTX insiders net buyers or net sellers?

Across the full Form 4 history for AKTX, 37 transactions (40%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does AKTX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is AKTX in?

Akari Therapeutics Plc (AKTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $11.75M.

AKTX insider trading

NasdaqCM Healthcare

Akari Therapeutics Plc — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

40% / 0%

Market cap

$11.75M

About Akari Therapeutics Plc

Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Boston, Massachusetts.

Company website: www.akaritx.com

AKTX insider activity at a glance

FilingIQ has scored 93 insider transactions for AKTX since Nov 25, 2015. The most recent filing in our index is dated Jun 24, 2026.

Across the full history, 37 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on AKTX insider trades is 50.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live AKTX trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,213

UNITED THERAPEUTICS Corp

APLS 275

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

GH 191

Guardant Health, Inc.

KYMR 178

Kymera Therapeutics, Inc.

First Tracks Biotherapeutics, Inc.

Frequently asked

How many insider trades does FilingIQ track for AKTX?: FilingIQ tracks 93 Form 4 insider transactions for AKTX (Akari Therapeutics Plc), covering filings from Nov 25, 2015 onwards. 9 of those were filed in the last 90 days.
Are AKTX insiders net buyers or net sellers?: Across the full Form 4 history for AKTX, 37 transactions (40%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does AKTX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is AKTX in?: Akari Therapeutics Plc (AKTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $11.75M.

Methodology & sources

Every AKTX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.